Literature DB >> 29317480

miR-205 targets angiogenesis and EMT concurrently in anaplastic thyroid carcinoma.

Haleh Vosgha1, Armin Ariana2, Robert Anthony Smith1,3, Alfred King-Yin Lam2.   

Abstract

The current study aims to evaluate for the first time the inhibitory roles of miR-205 in the pathogenesis of anaplastic thyroid carcinoma. In addition, we investigated the mechanisms by which miR-205 regulates angiogenesis and epithelial-to-mesenchymal transition (EMT) in cancer. Two anaplastic thyroid carcinoma cell lines were transfected with the expression vector pCMV-MIR-205 Selected markers of angiogenesis and EMT including vascular endothelial growth factor A (VEGF-A) and zinc finger E-box-binding homeobox 1 (ZEB1) were investigated by Western blot. The interaction of miR-205 expression with EMT and angiogenesis were also investigated by assessment of matrix metalloproteinases 2 and 9 (MMP2 and MMP 9), SNAI1 (Snai1 family zinc finger 1), vimentin, E-cadherin and N-cadherin. The function of miR-205 was further tested with VEGF enzyme-linked immunosorbent assay (ELISA), wound healing, invasion and tube formation assays. Using an animal model, we studied the association of miR-205 with angiogenesis, proliferation and invasion. The following results were obtained. Permanent overexpression of miR-205 significantly suppressed angiogenesis and EMT by simultaneously targeting VEGF-A, ZEB1 and downstream products. Ectopic expression of miR-205 in cancer cells led to decreased migration, invasion and tube formation of endothelial cells. In addition, inhibition of tumour growth, vascularisation and invasion were noted in the mouse tumour xenografts. Our findings provide insights into simultaneous regulatory role of miR-205 in the pathogenesis of anaplastic thyroid carcinoma by suppressing both angiogenesis and EMT. This may open avenues to exploit miR-205 as an alternative cancer therapeutic strategy in the future.
© 2018 Society for Endocrinology.

Entities:  

Keywords:  EMT; anaplastic thyroid carcinoma; angiogenesis; invasion; miRNA-205

Mesh:

Substances:

Year:  2018        PMID: 29317480     DOI: 10.1530/ERC-17-0497

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  24 in total

1.  Transcriptional regulatory model of fibrosis progression in the human lung.

Authors:  John E McDonough; Farida Ahangari; Qin Li; Siddhartha Jain; Stijn E Verleden; Jose Herazo-Maya; Milica Vukmirovic; Giuseppe DeIuliis; Argyrios Tzouvelekis; Naoya Tanabe; Fanny Chu; Xiting Yan; Johny Verschakelen; Robert J Homer; Dimitris V Manatakis; Junke Zhang; Jun Ding; Karen Maes; Laurens De Sadeleer; Robin Vos; Arne Neyrinck; Panayiotis V Benos; Ziv Bar-Joseph; Dean Tantin; James C Hogg; Bart M Vanaudenaerde; Wim A Wuyts; Naftali Kaminski
Journal:  JCI Insight       Date:  2019-11-14

2.  Uncovering the expression patterns and the clinical significance of miR-182, miR-205, miR-27a and miR-369 in patients with urinary bladder cancer.

Authors:  Nouha Setti Boubaker; Aymone Gurtner; Nesrine Trabelsi; Isabella Manni; Haroun Ayed; Ahmed Saadi; Zeineb Naimi; Meriem Ksontini; Mouna Ayadi; Ahlem Blel; Soumaya Rammeh; Mohamed Chebil; Giulia Piaggio; Slah Ouerhani
Journal:  Mol Biol Rep       Date:  2020-10-31       Impact factor: 2.316

3.  miR-155 overexpression is followed by downregulation of its target gene, NFE2L2, and altered pattern of VEGFA expression in the liver of melanoma B16-bearing mice at the premetastatic stage.

Authors:  Mariya B Aksenenko; Nadezhda V Palkina; Olga N Sergeeva; Ekaterina Yu Sergeeva; Andrey K Kirichenko; Tatiana G Ruksha
Journal:  Int J Exp Pathol       Date:  2020-02-11       Impact factor: 1.925

Review 4.  Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics.

Authors:  Ichiro Abe; Alfred King-Yin Lam
Journal:  Curr Oncol Rep       Date:  2021-02-13       Impact factor: 5.075

5.  Long noncoding RNA DLEU2 drives the malignant behaviors of thyroid cancer through mediating the miR-205-5p/TNFAIP8 axis.

Authors:  Jiwen Yang; Yayin Huang; Bohan Dong; Yunhai Dai
Journal:  Endocr Connect       Date:  2021-04-26       Impact factor: 3.335

6.  Targeting EZH2 as a novel therapeutic strategy for sorafenib-resistant thyroid carcinoma.

Authors:  Zhengshi Wang; Jiaqi Dai; Jie Yan; Yun Zhang; Zhiqiang Yin
Journal:  J Cell Mol Med       Date:  2019-05-13       Impact factor: 5.310

7.  Downregulation of hsa_circ_0001681 suppresses epithelial-mesenchymal transition in thyroid carcinoma via targeting to miR-942-5p/TWIST1 signaling pathway.

Authors:  Tianyi Wang; Yinpeng Huang
Journal:  J Bioenerg Biomembr       Date:  2021-06-23       Impact factor: 2.945

8.  Downregulation of miR-205 contributes to epithelial-mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1-RAGE signaling pathway.

Authors:  Ling Wang; Fu-Biao Kang; Juan Wang; Chao Yang; Dong-Wei He
Journal:  Anticancer Drugs       Date:  2019-03       Impact factor: 2.248

9.  miR-205-5p inhibits human endometriosis progression by targeting ANGPT2 in endometrial stromal cells.

Authors:  Chen-Fei Zhou; Min-Juan Liu; Wei Wang; Sha Wu; Yu-Xin Huang; Guo-Bin Chen; Li-Min Liu; Dong-Xian Peng; Xue-Feng Wang; Xu-Zi Cai; Xiao-Xuan Li; Wan-Qin Feng; Ying Ma
Journal:  Stem Cell Res Ther       Date:  2019-09-23       Impact factor: 6.832

10.  A proteogenomic portrait of lung squamous cell carcinoma.

Authors:  Shankha Satpathy; Karsten Krug; Pierre M Jean Beltran; Sara R Savage; Francesca Petralia; Chandan Kumar-Sinha; Yongchao Dou; Boris Reva; M Harry Kane; Shayan C Avanessian; Suhas V Vasaikar; Azra Krek; Jonathan T Lei; Eric J Jaehnig; Tatiana Omelchenko; Yifat Geffen; Erik J Bergstrom; Vasileios Stathias; Karen E Christianson; David I Heiman; Marcin P Cieslik; Song Cao; Xiaoyu Song; Jiayi Ji; Wenke Liu; Kai Li; Bo Wen; Yize Li; Zeynep H Gümüş; Myvizhi Esai Selvan; Rama Soundararajan; Tanvi H Visal; Maria G Raso; Edwin Roger Parra; Özgün Babur; Pankaj Vats; Shankara Anand; Tobias Schraink; MacIntosh Cornwell; Fernanda Martins Rodrigues; Houxiang Zhu; Chia-Kuei Mo; Yuping Zhang; Felipe da Veiga Leprevost; Chen Huang; Arul M Chinnaiyan; Matthew A Wyczalkowski; Gilbert S Omenn; Chelsea J Newton; Stephan Schurer; Kelly V Ruggles; David Fenyö; Scott D Jewell; Mathangi Thiagarajan; Mehdi Mesri; Henry Rodriguez; Sendurai A Mani; Namrata D Udeshi; Gad Getz; James Suh; Qing Kay Li; Galen Hostetter; Paul K Paik; Saravana M Dhanasekaran; Ramaswamy Govindan; Li Ding; Ana I Robles; Karl R Clauser; Alexey I Nesvizhskii; Pei Wang; Steven A Carr; Bing Zhang; D R Mani; Michael A Gillette
Journal:  Cell       Date:  2021-08-05       Impact factor: 66.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.